[{"id":"3667c333-38af-4510-8071-f43c069867f2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06154317","created_at":"2023-12-09T16:57:24.552Z","updated_at":"2024-07-02T16:35:27.199Z","phase":"","brief_title":"Study for Validation of Target Therapy in Multiple Myeloma Cells From Patients With miRNAs Released From B Cells, and Study of the Bone Marrow Tumor Microenvironment (Microenvironment of MM)","source_id_and_acronym":"NCT06154317","lead_sponsor":"Centro di Riferimento Oncologico - Aviano","biomarkers":" XBP1 • SOX4","pipe":"","alterations":" ","tags":["XBP1 • SOX4"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/16/2023","start_date":" 02/16/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2023-12-04"},{"id":"f0b947c0-82f0-451e-a0c9-2accffc8242c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01414426","created_at":"2021-01-18T05:49:22.754Z","updated_at":"2024-07-02T16:36:36.031Z","phase":"Phase 2","brief_title":"Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions","source_id_and_acronym":"NCT01414426","lead_sponsor":"University of Chicago","biomarkers":" SOX4","pipe":"","alterations":" ","tags":["SOX4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Caprelsa (vandetanib)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 01/01/2012","start_date":" 01/01/2012","primary_txt":" Primary completion: 01/01/2019","primary_completion_date":" 01/01/2019","study_txt":" Completion: 06/01/2019","study_completion_date":" 06/01/2019","last_update_posted":"2021-01-14"}]